Lorundrostat vs Vicadrostat
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Hypertension
Shared mechanism: Aldosterone synthase (CYP11B2) · full Hypertension pipeline
Lorundrostat
Developed by Mineralys Therapeutics and partners
NCT05769608 · Phase 2 · completed
This was a randomized, double-blind, placebo-controlled trial in 285 patients with uncontrolled hypertension that measured 24-hour ambulatory systolic blood pressure, the standard efficacy measure for this disease. The 50 mg lorundrostat dose lowered ambulatory blood pressure significantly more than placebo at week 12.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Reported efficacy
Change from baseline in automated office BP (AOBP) SBP at Week 6 in subjects randomized to lorundrostat 50 mg QD compared to subjects randomized to placebo: Launch-HTN: change from baseline in automated office SBP at Week 6, lorundrostat 50 mg vs placebo: -16.9 mmHg absolute reduction; -9.1 mmHg placebo-adjusted reduction (p<0.0001) (met)
Result source: NCT06153693
Vicadrostat
Developed by Boehringer Ingelheim
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2029 · NCT07064473 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Hypertension
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Lorundrostat | Vicadrostat |
|---|---|---|
| Seated SBP, change | —Not posted · NCT06153693 | —Trial running · NCT07064473 |
| 24-hour ambulatory SBP, change | —Not posted · NCT06153693 | —Trial running · NCT07064473 |
| Seated DBP, change | —Not posted · NCT06153693 | —Trial running · NCT07064473 |
Seated SBP, change
- Lorundrostat
- —Not posted · NCT06153693
- Vicadrostat
- —Trial running · NCT07064473
24-hour ambulatory SBP, change
- Lorundrostat
- —Not posted · NCT06153693
- Vicadrostat
- —Trial running · NCT07064473
Seated DBP, change
- Lorundrostat
- —Not posted · NCT06153693
- Vicadrostat
- —Trial running · NCT07064473
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Vicadrostat: no structured comparison results are available for Hypertension.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Lorundrostat: 2 of 4 rows · Vicadrostat: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Lorundrostat |
|---|---|
| Dropout rate | — NCT06150924 · Phase 2 · pooled · Chronic Kidney Disease, Hypertension · phase 2 |
| Discontinued due to AEs | — NCT06150924 · Phase 2 · pooled · Chronic Kidney Disease, Hypertension · phase 2 |
| Serious AEs | 3.4% NCT06150924 · Phase 2 · pooled · Chronic Kidney Disease, Hypertension · phase 2 |
| Most frequent reported AEs | hyperkalaemia 15.5% (placebo 3.5%) glomerular filtration rate decreased 10.3% (placebo 3.5%) hyponatraemia 5.2% (placebo 5.3%) NCT06150924 · Phase 2 · pooled · Chronic Kidney Disease, Hypertension · phase 2 |
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Lorundrostat
Chronic Kidney Disease
Shared mechanism: Aldosterone synthase (CYP11B2) · full Chronic Kidney Disease pipeline
Lorundrostat
Developed by Mineralys Therapeutics and partners
NCT06150924 · Phase 2 · completed
Explore-CKD was a randomized, double-blind, placebo-controlled, two-period crossover Phase 2 trial of lorundrostat 25 mg on top of an SGLT2 inhibitor in about 60 patients with hypertension and albuminuric chronic kidney disease. The primary endpoint was the placebo-adjusted change in automated office systolic blood pressure at week 4: -7.5 mmHg (p=0.0024), and the sponsor states the trial met the primary endpoint. Sources: CT.gov posted results and the Mineralys press release filed on SEC Form 8-K.
Reported efficacy
Placebo-adjusted Change From Baseline in Automated Office Blood Pressure (AOBP) Systolic Blood Pressure (SBP) at Week 4 (Baseline to Week 4): Automated office systolic blood pressure at week 4: lorundrostat 25 mg -9.25 mmHg vs placebo -1.76 mmHg (CT.gov LS means, n=58 per period); placebo-adjusted -7.5 mmHg (p=0.0024) (Mineralys release, 17 Jun 2025, SEC 8-K). (met)
Result source: NCT06150924
Vicadrostat
Developed by Boehringer Ingelheim
NCT06531824 · Phase 3 · active, not recruiting
This was a randomized, quadruple-masked Phase 3 trial with 8371 participants. Its primary endpoint was not met according to the sponsor's announcement of 2026-09-01. A well-designed trial whose primary comparison was not met, or only partly met, is graded moderate.
Next expected readout: December 2026 · NCT06531824 (registry estimate)
Reported efficacy
Time to first occurrence of the primary composite outcome of: (i) Kidney disease progression*; or (ii) Hospitalization for heart failure; or (iii) Cardiovascular death. (up to 4 years): Discontinued by Boehringer Ingelheim on an independent Data Monitoring Committee recommendation: accumulating data did not support a meaningful expectation of benefit on the primary composite endpoint vs empagliflozin alone (September 2026). (missed)
Result source: NCT06531824
Results for Chronic Kidney Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.
| Key endpoint | Lorundrostat | Vicadrostat |
|---|---|---|
| Kidney composite outcome | —Not reported | —Trial running · NCT06531824 |
| UACR, % change | —Not reported | -38.5% vs -6.4%−32.1 vs placeboNCT051828408 other results
|
| eGFR slope | —Not reported | —Trial running · NCT06531824 |
| Haemoglobin, change | —Not reported | —Trial running · NCT06531824 |
Kidney composite outcome
- Lorundrostat
- —Not reported
- Vicadrostat
- —Trial running · NCT06531824
UACR, % change
- Lorundrostat
- —Not reported
- Vicadrostat
- -38.5% vs -6.4%−32.1 vs placeboNCT05182840
8 other results
- -36.6% vs -2.6% NCT05182840
- -42.5% vs -6.4% NCT05182840
- -39.1% vs -2.6% NCT05182840
- -20.9% vs -6.4% NCT05182840
- -22.4% vs -2.6% NCT05182840
- -19% vs -10.6% NCT05182840
- -45.9% vs -10.6% NCT05182840
- -40.3% vs -10.6% NCT05182840
eGFR slope
- Lorundrostat
- —Not reported
- Vicadrostat
- —Trial running · NCT06531824
Haemoglobin, change
- Lorundrostat
- —Not reported
- Vicadrostat
- —Trial running · NCT06531824
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Lorundrostat: 2 of 4 rows · Vicadrostat: 2 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Lorundrostat | Vicadrostat |
|---|---|---|
| Dropout rate | — NCT06150924 · Phase 2 · pooled · Chronic Kidney Disease, Hypertension · phase 2 | —20 mga NCT05182840 · Phase 2 show 5 more results—10 mg + 10 mg NCT05182840 · Phase 2 · combination —10 mg + 20 mg NCT05182840 · Phase 2 · combination —10 mg + 3 mg NCT05182840 · Phase 2 · combination —10 mg NCT05182840 · Phase 2 —3 mg NCT05182840 · Phase 2 |
| Discontinued due to AEs | — NCT06150924 · Phase 2 · pooled · Chronic Kidney Disease, Hypertension · phase 2 | —20 mga NCT05182840 · Phase 2 show 5 more results—10 mg + 10 mg NCT05182840 · Phase 2 · combination —10 mg + 20 mg NCT05182840 · Phase 2 · combination —10 mg + 3 mg NCT05182840 · Phase 2 · combination —10 mg NCT05182840 · Phase 2 —3 mg NCT05182840 · Phase 2 |
| Serious AEs | 3.4% NCT06150924 · Phase 2 · pooled · Chronic Kidney Disease, Hypertension · phase 2 | 8.3%20 mga NCT05182840 · Phase 2 show 5 more results9.6%10 mg + 10 mg NCT05182840 · Phase 2 · combination 6.8%10 mg + 20 mg NCT05182840 · Phase 2 · combination 5.3%10 mg + 3 mg NCT05182840 · Phase 2 · combination 5.6%10 mg NCT05182840 · Phase 2 4.3%3 mg NCT05182840 · Phase 2 |
| Most frequent reported AEs | hyperkalaemia 15.5% (placebo 3.5%) glomerular filtration rate decreased 10.3% (placebo 3.5%) hyponatraemia 5.2% (placebo 5.3%) NCT06150924 · Phase 2 · pooled · Chronic Kidney Disease, Hypertension · phase 2 | 20 mga hyperkalaemia 23.6% (placebo 5.5%) glomerular filtration rate decreased 8.3% (placebo 4.1%) upper respiratory tract infection 4.2% (placebo 2.7%) NCT05182840 · Phase 2 show 5 more results10 mg + 10 mg hyperkalaemia 15.1% (placebo 5.5%) glomerular filtration rate decreased 11% (placebo 4.1%) hypotension 5.5% (placebo 0%) NCT05182840 · Phase 2 · combination 10 mg + 20 mg glomerular filtration rate decreased 9.5% (placebo 4.1%) hyperkalaemia 9.5% (placebo 5.5%) upper respiratory tract infection 5.4% (placebo 2.7%) NCT05182840 · Phase 2 · combination 10 mg + 3 mg hyperkalaemia 6.6% (placebo 5.5%) glomerular filtration rate decreased 5.3% (placebo 4.1%) cortisol decreased 2.6% (placebo 0%) NCT05182840 · Phase 2 · combination 10 mg glomerular filtration rate decreased 9.9% (placebo 4.1%) hyperkalaemia 9.9% (placebo 5.5%) cortisol decreased 5.6% (placebo 0%) NCT05182840 · Phase 2 3 mg hyperkalaemia 11.4% (placebo 5.5%) cortisol decreased 4.3% (placebo 0%) upper respiratory tract infection 2.9% (placebo 2.7%) NCT05182840 · Phase 2 |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Lorundrostat
Vicadrostat
show 8 more results
show 8 more results
show 35 more results
show 35 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Lorundrostat's landscape · Vicadrostat's landscape